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The persistence of latent HIV-infected cellular reservoirs
represents the major hurdle to virus eradication with
highly active anti-retroviral therapy (HAART), since
latently infected cells remain a permanent source of viral
reactivation. HIV establishes a persistent infection in CD4
+ T lymphocytes (and to a lesser extent in macrophages as
well), creating a persistent reservoir consisting mainly of
latently infected resting memory CD4+ T cell. Although
pre- and post-integration latencies have been described in
HIV-1, the reservoir that appears to be the major barrier
to eradication is composed of latently infected cells carry-
ing an integrated provirus that is transcriptionally silent.
It has been suggested that reactivation of the latent
reservoirs could allow effective targeting and possible
eradication of the virus. Immunoactivation therapy to
reduce the latent pool of HIV by treatment with the anti-
CD3 antibody OKT-3 alone or in combination with
interleukin-2, substantially failed to significantly decrease
the viral reservoir. Non-specific T-cell activation may
induce high-level viral replication above a level that can
be fully contained by ART, while increasing the suscept-
ibility of uninfected cells.
Selective targeting of HIV provirus via agents that
induce the expression of quiescent HIV, but have limited
effects on the uninfected host cell is an alternate
approach to attack latent HIV. Activation from latency to
completion of the replication cycle should result in lytic
cell death of CD4+ T cells. Multiple mechanisms that
contribute to the maintenance of proviral latency could
be targeted to activate the latent virus. As examples of
potentially useful agents, IL–7 can reactivate HIV–1i n
latently infected cells in vitro through the induction of
the Janus kinase–signal transducer and activator of tran-
scription (JAK–STAT) signalling pathway. The use of dif-
ferent chemical compounds targeting the PKC signalling
pathway (prostratin, bryostatin) has also been proposed
as a means of reactivating viral reservoirs. Finally, HDAC
blocking is an attractive potential means of inducing
broad reactivation of HIV–1 reservoirs, and promising
results have been achieved using the HDAC inhibitor
vorinostat.
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